MAPT and Alzheimer disease: The capacity of protein quality control and degradation (proteostasis) declines with aging, facilitating neurodegeneration as exemplified by the late onset of excessive accumulation of amyloid-beta peptide (Aβ) and tau in Alzheimer’s disease, and α-synuclein in Parkinson’s disease [64].